While approved by the Medicines and Healthcare products Regulatory Agency, the Alzheimer’s drug failed to win the backing of the U.K.’s National Institute for Health and Care Excellence, which said that its benefits were “too small to justify the cost.”
Tag Archive for: Biogen
The drugmaker has cut jobs, bolstered its pipeline for rare disease medicines through takeover deals and unveiled new products, such as Alzheimer’s disease drug Leqembi, as part of a plan to return to growth.
The benefit of Eisai and Biogen’s Alzheimer’s drug Leqembi in patients with early-stage Alzheimer’s appears to increase with continued use with no new safety issues, according to three-year data presented at an Alzheimer’s meeting on Tuesday.
The European Union’s drugs regulator has rejected Eisai and Biogen’s breakthrough treatment for early Alzheimer’s disease, it said on Friday, in a blow to the drugmakers as take-up in the U.S. has been slower than expected.
Biogen and Sage Therapeutics do not plan to conduct further studies for their neurological disorder drug after it failed in a mid-stage trial, the drugmakers said on Wednesday.
Donanemab, which will be marketed as Kisunla, will compete with Biogen and Eisai’s Leqembi.
The companies have launched their Alzheimer’s treatment Leqembi in China, the third country after the United States and Japan.
Italy’s antitrust regulator said it launched an investigation into pharmaceutical companies including Novartis and Roche-controlled Genentech for having potentially restricted competition in the sale of an eye drug.
This year has seen a boom in biopharma mergers and acquisitions, with six acquisitions over a billion dollars so far. In light of the massive revenues pharma companies are generating in the obesity space and the pressure many companies are under from looming loss of exclusivity (LOE) on top drugs, analysts don’t see it slowing down anytime soon.
The company announced today that it had agreed to buy privately held Human Immunology Biosciences for up to $1.8 billion, bulking up on rare disease medicines as its older multiple sclerosis drugs face tepid demand due to rising competition.